Mepartricin: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 38: | Line 38: | ||
[[Category:Candidiasis]] | [[Category:Candidiasis]] | ||
{{medicine-stub}} | {{medicine-stub}} | ||
<gallery> | |||
File:Mepartricin A.png|Mepartricin | |||
</gallery> | |||
Latest revision as of 01:30, 20 February 2025
Mepartricin is a macrolide antibiotic that is used primarily in the treatment of prostatitis and benign prostatic hyperplasia (BPH). It is not absorbed from the gastrointestinal tract and works by inhibiting the growth of certain types of bacteria.
History[edit]
Mepartricin was first isolated in the 1960s from the fermentation broth of a strain of Streptomyces aureofaciens. It was initially used in veterinary medicine before being approved for use in humans.
Mechanism of Action[edit]
Mepartricin inhibits the growth of bacteria by binding to the bacterial ribosome, specifically the 50S subunit. This prevents the formation of a functional 70S initiation complex, which is essential for the bacterial protein synthesis.
Medical Uses[edit]
Mepartricin is used in the treatment of prostatitis and BPH. It is also used in the treatment of candidiasis, a fungal infection caused by Candida species.
Side Effects[edit]
Common side effects of mepartricin include nausea, vomiting, diarrhea, and abdominal pain. In rare cases, it can cause allergic reactions.
Pharmacokinetics[edit]
Mepartricin is not absorbed from the gastrointestinal tract. It is excreted in the feces.
See Also[edit]
References[edit]
<references group="" responsive="1"></references>
-
Mepartricin
